Nuzenio

Replimune

Replimune news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 24 latest news signals 18 publisher sources 100/100 entity strength

Latest news

FDA Approves Replimune's Tudriqev for Advanced Melanoma After Two Previous Rejections - medicaldaily.commedicaldaily.com · Sat, 08 Aug 2026 14:30:41 GMTReplimune Group Price Target Raised to $20.00/Share From $17.00 by JP Morgan - MoomooMoomoo · Sat, 08 Aug 2026 01:48:35 GMTRecovery for Replimune: Accelerated Approval for Cancer Drug Twice Spurned by FDA - MedCity NewsMedCity News · Fri, 07 Aug 2026 22:12:34 GMTREPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law - Business WireBusiness Wire · Fri, 07 Aug 2026 21:07:00 GMTAmid political outcry, advisors accept weak data and give sponsor a chance to complete phase III trial - The Cancer LetterThe Cancer Letter · Fri, 07 Aug 2026 20:50:43 GMTDeadline Soon: Replimune Group, Inc. (REPL) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit - Business WireBusiness Wire · Fri, 07 Aug 2026 18:40:00 GMTThird Time's the Charm: FDA Approves Replimune's Tudriqev (RP1) for Advanced Melanoma - OncodailyOncodaily · Fri, 07 Aug 2026 18:18:14 GMTFDA Grants Accelerated Approval to Replimune's Tudriqev Plus Nivolumab for Advanced Melanoma - BioPharm InternationalBioPharm International · Fri, 07 Aug 2026 17:19:39 GMT

Timeline

Sat, 08 Aug 2026 14:30:41 GMTFDA Approves Replimune's Tudriqev for Advanced Melanoma After Two Previous Rejections - medicaldaily.com
Sat, 08 Aug 2026 01:48:35 GMTReplimune Group Price Target Raised to $20.00/Share From $17.00 by JP Morgan - Moomoo
Fri, 07 Aug 2026 22:12:34 GMTRecovery for Replimune: Accelerated Approval for Cancer Drug Twice Spurned by FDA - MedCity News
Fri, 07 Aug 2026 21:07:00 GMTREPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law - Business Wire
Fri, 07 Aug 2026 20:50:43 GMTAmid political outcry, advisors accept weak data and give sponsor a chance to complete phase III trial - The Cancer Letter
Fri, 07 Aug 2026 18:40:00 GMTDeadline Soon: Replimune Group, Inc. (REPL) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit - Business Wire

Related explainers

ElectionsElection stories need careful handling because polls, turnout, legal challenges, and campaign claims can change quickly.HealthHealth stories help readers understand public-health signals, medical research, hospital systems, medicines, disease updates, and safety guidance.PoliticsPolitics stories explain decisions, institutions, parties, leaders, laws, budgets, elections, courts, and public accountability.EconomyEconomy stories explain how money, jobs, prices, policy, trade, and business confidence affect daily life.

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Replimune.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

18 distinct publisher/source names are currently connected to this entity page.